This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.
Approximately 230,000 women are diagnosed with invasive breast cancer and 60,000 women are diagnosed with ductal carcinoma in situ (DCIS) (breast cancer in the breast milk ducts) annually in the US. Most women choose to be treated with breast conserving surgery (BCS). The goal of BCS is to resect the tumor with a surrounding margin of tissue free of cancer, and to minimize the volume of tissue removed, thereby preserving the overall shape and appearance of the breast.
We propose to develop an economic in-office pain tests that may help screen and differentiate patients with neuropathic corneal pain (NCP) that could be used at any ophthalmic office. These five in-office pain tests include response with filter glasses, moisture googles, cold saline, hypertonic saline and topical proparcaine.
This study is being conducted in healthy children from age 6 months to age 12 years. The study is looking at how well the Moderna mRNA vaccine works when given to healthy children for the prevention of COVID-19.
This patient registry aims to recruit people who have recovered following infection with SARS-CoV-2 / COVID-19 for the purpose of connecting them with researchers in the United States who are conducting research to learn about the survivor experience, and develop new treatments for patients currently with the illness.
This is a research study being conducted in patients who tested positive for COVID-19 in the past 10 days and are admitted to the hospital. The study is being conducted to assess the safety of an experimental drug called Reparixin. This is provided as tablets along with standard treatment to limit progression of Covid-19 disease. This is a randomized, (which means just like tossing a coin, you will be randomly assigned to receive the study drug or the standard treatment) double-blind trial (which means neither you nor the study team will know which group you are assigned to).
The primary aim of this study is to obtain observational physiological signals from patients previously discharged from hospitalization at Tufts Medical Center between 2019 to present (est enrollment starting in June 2022) with positive diagnosis of COVID-19 to further our understanding and characterization of Long COVID-19 syndrome using combined medical histories and continuous physiological signals captured through wearable devices such as the Oura Ring, Fitbit, AliveCor KardiaMobile, and Samsung Watch3 type devices.
This is a prospective, multi-center, non-randomized, single arm, post-approval study. The main objective of this study is collection of the real world safety and effectiveness outcomes of the TREO Abdominal Stent-Graft System in an all-comers population eligible for the endovascular treatment of abdominal aortic aneurysm (AAA) in routine clinical practice, with emphasis on subjects that experience a device stent-strut or barb fracture.
The study is seeking to create a repository of blood samples from participants who have a history of testing positive for COVID-19 to help accelerate current and future COVID-19 research.
Open label trial of letermovir for secondary prophylaxis for solid organ transplant recipients at risk of relapsing cytomegalovirus infection and disease
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone [R-miniCHOP]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the lymphoma cells and may help the immune system kill these cells.
This prospective, single center, randomized, double-masked, parallel comparison, sponsored study seeks to investigate the efficacy of IDI on ameliorating the signs and symptoms of dry eye disease. The study aims to enroll 54 patients (36 Dextenza commercial formulation, 18 Collagen Plug) with DED.
This is a single site, prospective, cross-sectional, controlled clinical study on a total of 66 subjects. The subjects are divided into two groups: HS non-responders (33 subjects) and HS responders (33 subjects). After completion of questionnaires, the subjects will undergo DED testing and functional nerve testing. Subjects who qualify will be dispensed 4 weeks of preservative free artificial tears and instructed to instill one drop into each eye twice daily.
This study is designed to test a potential biomarker to identify NCP patients. A biomarker is a characteristic that is unique to NCP patients and will help to identify them from DED patients so that correct treatment can be provided to them.
Age-related macular degeneration (AMD) is a disease that affects the retina, an integral part of the eye responsible for sensing light and relaying images to the brain. In the United States, AMD is the leading cause of irreversible vision loss as people age. Previous studies have shown that the nutrients lutein and zeaxanthin can help protect against AMD in middle aged and older adults. These nutrients form a pigment in the retina (macular pigment) that helps protect the retina from light damage.
Eligible subjects are selected from a registry maintained by the Clinical Site: Cornea Research Foundation of America (CRFA) In Indianapolis. Registry patients are individuals who underwent corneal surgery at the Price Vision Group and whose intraocular pressure was tracked over at least a 6-month period following their surgery and follow-up treatment with steroids. The patients" clinical data resides in the registry. Thus, ONLY CRFA registry patients are eligible for recruitment to the study.
This is a Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study, with the objective of comparing Progression-Free Survival (PFS) in newly diagnosed GBM patients treated with IGV-001 with patients treated with placebo.
Utilize fresh tumor tissue to aid the development of future therapies for brain cancer.
Briefly, a cell immunotherapy consisting of a patient’s autologous glioblastoma tumor cells, called ‘IGV-001’, is being tested in clinical trials. In order to advance clinical and product development of IGV-001, Imvax is seeking access to patient material to test key product parameters in a laboratory setting.
This is a phase I trial to see whether patients are able to adhere to a modified, high fat/low carbohydrate diet (the sHFLC + KetoPhyt Diet) with a supplement named KetoPhyt that includes ketones and anti-inflammatory properties.
The classic ketogenic diet (KD) is difficult for patients to adhere to due to its stringent nature. A modified KD has been developed that mimics the glucose lowering, ketone raising effects and the anti-cancer outcomes of the KD.
